Illumina Announces Launch of Custom Methylation Application
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has announced that it has added a custom-content methylation product to its growing portfolio of DNA analysis tools. Custom-content design provides researchers with the flexibility to perform genome-wide methylation profiling specific to individual study goals.
Joining Illumina's GoldenGate Methylation Cancer Panel I, the Company's first standard methylation product launched in January 2007, investigators now have the option to select their favorite genes or gene regions to survey up to 1,536 methylation sites of choice across 96 samples simultaneously.
"Custom methylation adds another degree of integration to analysis with genetic and epigenetic data. Researchers who are interested in expediting the speed and scope of their methylation studies in areas such as cancer, developmental disorders, stem cell, aging and neurological diseases now have the ability to select specific CpG sites from chosen genes" said Marina Bibikova, Ph.D., Staff Scientist at Illumina.
As part of The Cancer Genome Atlas (TCGA) Pilot Project the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University and the Norris Comprehensive Cancer Center of the University of Southern California were granted funds to use Illumina's technology to detect changes in methylation profiles associated with transcribed genes in cancer. This will be the first high-profile custom methylation project on Illumina's GoldenGate Methylation platform, expected to be completed by mid 2007.
